Pulmonary sarcoidosis full details for md exams 15marks answer from fishman and murray

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive, detailed content from both Fishman's and Murray & Nadel's. Let me compile the full 15-mark MD exam answer.

Pulmonary Sarcoidosis - Comprehensive MD Exam Answer (15 Marks)

Sources: Fishman's Pulmonary Diseases and Disorders (Chapter 53 - Systemic Sarcoidosis) and Murray & Nadel's Textbook of Respiratory Medicine (Chapter 93)

1. DEFINITION

Sarcoidosis is a systemic disorder characterized by noncaseating (non-necrotizing) granulomatous inflammation at sites of disease. Although any organ can be involved, the disease most commonly affects the lungs and intrathoracic lymph nodes. The diagnosis requires a compatible clinical and radiographic presentation, confirmed by biopsy showing noncaseating epithelioid granulomas in more than one organ, with exclusion of granulomatous disorders of known cause.

Fishman's Pulmonary Diseases and Disorders, p. 922

2. HISTORICAL EPONYMS (High-Yield for Exams)

Eponym	Description
Hutchinson/Boeck disease	Original description of cutaneous "Mortimer's malady" (1870s-1890s)
Löfgren syndrome	Acute sarcoidosis triad: erythema nodosum + bilateral hilar adenopathy + periarticular ankle inflammation/arthritis; high rate of spontaneous remission
Heerfordt (uveoparotid fever)	Uveitis + parotitis + fever + bilateral hilar adenopathy; diagnosis without biopsy
Panda sign	Bilateral parotid + lacrimal gland uptake on gallium-67 scan
Lambda sign	Bilateral hilar + right paratracheal lymph node uptake on gallium-67
Kveim test	Intradermal injection of sarcoidosis tissue extract - forms granuloma in 4-6 weeks; >80% sensitivity; historically used, now abandoned due to biosafety concerns
Schaumann bodies	Lamellated calcified inclusions in giant cells
Asteroid bodies	Star-shaped inclusions in giant cells
Hamazaki-Wesenberg bodies	Pigmented oval inclusions

Fishman's, p. 922; Murray & Nadel's, p. 2134

3. EPIDEMIOLOGY

Worldwide distribution: highest prevalence in Scandinavia (Sweden: 160/100,000 prevalence); geographic clustering in Ireland and Italy suggests environmental triggers
United States: highest prevalence in southeastern coastal states
Racial disparities: Black Americans have higher incidence (17.8/100,000/year) vs. white Americans (8.1/100,000), higher mortality, and more severe disease (lupus pernio, cardiac involvement more common)
Age of onset: Peak 40-55 years (not young adulthood as previously thought); possibly bimodal - younger males and older females
Gender: Males have higher prevalence in Sweden but Black American women in the US have the highest risk
Genetics: Higher prevalence among first-degree relatives; HLA genes (MHC locus) show strongest genetic association; NOD2 mutations linked to Blau syndrome (pediatric granulomatous disease)
Mortality: Lung fibrosis, pulmonary hypertension, and older age are risk factors for death; deaths significantly higher in Black Americans
Fishman's, pp. 922-924

4. ETIOLOGY AND PATHOGENESIS

Proposed Etiology

Sarcoidosis results from the combined effects of genetic susceptibility and environmental/microbial exposures, triggering aberrant immune responses. No single causative agent identified.

Candidate antigens include:

Mycobacterial antigens: mKatG (mycobacterial catalase-peroxidase) and ESAT-6 are the most-studied candidate pathogenic antigens, provoking adaptive T-cell responses in subsets of patients
Propionibacterium acnes (especially in Japanese patients)
Organic dusts, metals (beryllium), and inorganic particles

Immunopathogenesis (Key Steps)

Step 1 - Innate immune activation:

Microbial/environmental antigens activate innate receptors: TLR2 (Toll-like receptor 2) and NOD1/NOD2 pathways
Serum amyloid A (SAA) is an endogenous TLR2 ligand expressed in sarcoidosis tissues - drives TNF production, creating a positive feedback loop of granulomatous inflammation
Enhanced TLR2 responsiveness found in blood and BAL cells from sarcoidosis patients

Step 2 - Adaptive immune response (granuloma formation):

CD4+ T helper cells (Th1 skewed) predominate: produce IFN-γ, TNF, IL-2, IL-12
IFN-γ and TNF (from "multifunctional" CD4+ T cells) drive macrophage activation into epithelioid cells
CD4:CD8 ratio in BAL is elevated (>3.5:1) - a characteristic finding (normal ~1.7:1)
Granuloma forms: central core of epithelioid macrophages + multinucleated giant cells surrounded by CD4+ T lymphocytes peripherally, with CD8+ suppressor T cells in the outer rim

Step 3 - Lung fibrosis:

TGF-β (transforming growth factor-beta) is the key mediator of fibrosis in sarcoidosis
Disease-specific T-cell and macrophage activation promotes progressive fibrosing inflammation in a subset of patients
Th17 pathway has also been implicated in fibrotic sarcoidosis
Fishman's, pp. 925-931; Murray & Nadel's

5. PATHOLOGY

The histologic hallmark is the non-necrotizing (non-caseating) granuloma:

Compact, well-formed rounded aggregates of epithelioid macrophages
Multinucleated giant cells (formed by macrophage fusion)
Peripheral rim of lymphocytes (CD4+ T cells)
No significant necrosis - necrosis strongly favors infection
Inclusions (non-specific, non-diagnostic): Schaumann bodies, asteroid bodies, Hamazaki-Wesenberg bodies, birefringent crystals
Surrounded by variable fibrosis/sclerotic stroma in established lesions

Pulmonary Distribution - The "Lymphangitic" Pattern (Pathognomonic)

Sarcoidal granulomas follow lymphatic routes in the lung, producing the characteristic "perilymphatic" distribution seen on HRCT:

Along bronchovascular bundles
Along interlobular septa
Along the pleura (subpleural)
Mediastinal lymph node involvement in most cases

Pulmonary Sarcoidosis Histology: (A) Perilymphatic distribution of parenchymal nodules at low magnification (H&E ×6). (B) Well-formed coalescing granulomas lacking necrosis, surrounded by fibrosis (H&E ×100)

Figure: Pulmonary sarcoidosis histopathology - Murray & Nadel's Textbook of Respiratory Medicine

Special stains routinely performed: Acid-fast bacilli (AFB) stain to exclude mycobacteria; Gomori methenamine silver (GMS) to exclude fungi.

Murray & Nadel's, pp. (block 6); Fishman's, p. 931

6. CLINICAL FEATURES

Presentation Patterns

A. Asymptomatic (30-50%): Discovered incidentally on chest X-ray (e.g., bilateral hilar adenopathy on pre-employment screening)

B. Acute (Löfgren syndrome): Erythema nodosum + bilateral hilar adenopathy + periarticular ankle inflammation; fever; predominantly in white Europeans and Puerto Ricans; excellent prognosis with spontaneous remission >90%

C. Subacute/chronic: Insidious dyspnea, dry cough, chest tightness; constitutional symptoms (fatigue, weight loss, fever, night sweats)

Pulmonary Features

Dyspnea (most common symptom in pulmonary disease)
Dry cough
Chest pain (pleuritic or atypical)
Wheezing (from endobronchial involvement or airway hyperresponsiveness)
Hemoptysis (uncommon; occurs with fibrocystic disease or Aspergillus colonization)
Respiratory failure (advanced fibrotic disease)

Extrapulmonary Manifestations

Organ	Frequency	Key Features
Lymph nodes	>90% (intrathoracic); peripheral ~30%	Bilateral hilar adenopathy; painless peripheral lymphadenopathy
Eye	20-30%	Anterior uveitis most common; also conjunctivitis, optic neuritis; can cause blindness
Skin	20-30%	Lupus pernio (violaceous nasal plaques - specific to sarcoidosis), erythema nodosum (non-granulomatous), plaques, subcutaneous nodules
Liver	~50-70% (pathologic); <30% symptomatic	Hepatomegaly, elevated ALP, portal hypertension (rare)
Spleen	~40% (pathologic)	Splenomegaly, cytopenias
Bone marrow	variable	Cytopenias, hypercalcemia
Cardiac	<10% clinical; >20% autopsy (US); >50% autopsy (Japan)	Arrhythmias, AV block, sudden death, dilated cardiomyopathy
Neurologic (Neurosarcoidosis)	~5-10%	Cranial nerve palsies (CN VII most common), aseptic meningitis, hypothalamic/pituitary involvement (diabetes insipidus), myelopathy
Upper respiratory	5-10%	Nasal congestion, epistaxis, saddle nose deformity; laryngeal sarcoidosis (hoarseness, stridor)
Musculoskeletal	~10-15%	Acute polyarthropathy (Löfgren), bone cysts (punched-out lesions), myopathy
Renal	~5%	Hypercalciuria → nephrolithiasis; granulomatous nephritis; nephrocalcinosis
Endocrine	rare	Hypercalcemia (activated macrophages produce 1,25-OH vitamin D), diabetes insipidus (pituitary/hypothalamic involvement)
Parotid/Lacrimal	rare	Heerfordt syndrome (uveoparotid fever): diagnostic without biopsy

Note on Hypercalcemia: Caused by ectopic production of 1,25-dihydroxyvitamin D (calcitriol) by activated macrophages within granulomas - a key high-yield mechanism.

Fishman's, pp. 928-934

7. CHEST RADIOGRAPHIC STAGING (Scadding Classification)

Stage	Radiographic Finding	Prevalence at Presentation	Remission Rate
Stage 0	Normal chest radiograph	~5-10%	-
Stage I	Bilateral hilar lymphadenopathy (BHL) alone	~50%	60-80% (high spontaneous remission)
Stage II	BHL + pulmonary infiltrates/parenchymal opacities	~25%	40-70%
Stage III	Pulmonary infiltrates WITHOUT hilar adenopathy	~15%	10-20%
Stage IV	Pulmonary fibrosis (fibrocystic stage)	~5%	Poor; irreversible

Stage I has the best prognosis - up to 80% spontaneous remission. Staging does not perfectly predict progression or treatment response.

Fishman's; Murray & Nadel's

8. HIGH-RESOLUTION CT (HRCT) FINDINGS

The HRCT pattern reflects the perilymphatic distribution:

Bilateral upper lobe predominance of micronodules (2-5 mm)
Perilymphatic/bronchovascular distribution - nodules cluster along bronchovascular bundles, interlobular septa, and pleura
Bilateral hilar and mediastinal lymphadenopathy - often "eggshell" calcification in chronic disease
"Galaxy sign" - large conglomerate masses with satellite micronodules (highly specific)
"Sarcoid cluster sign" / beaded fissures
Ground-glass opacity (active alveolitis)
Advanced/stage IV: traction bronchiectasis, honeycombing, bullae, cysts, fibrocystic upper lobe scarring with hilar retraction upward

9. PULMONARY FUNCTION TESTS (PFTs)

Pattern	Finding	Explanation
Restrictive (most common)	↓ FVC, ↓ TLC, FEV1/FVC normal or ↑	Granulomatous infiltration + fibrosis
Obstructive (~30%)	↓ FEV1/FVC	Endobronchial involvement, airway granulomas, large-airway compression by nodes
Mixed	Both patterns	Advanced disease
DLCO (diffusing capacity)	Reduced (early sensitive marker)	Gas exchange impairment, alveolitis
6-minute walk test	↓ Distance, desaturation	Exercise-induced hypoxemia

Spirometry, diffusing capacity (DLCO), and lung volumes are the recommended initial PFTs for all sarcoidosis patients.

10. DIAGNOSIS

Diagnostic Criteria

Compatible clinical + radiographic presentation
Histologic confirmation: Noncaseating epithelioid granulomas in ≥1 organ
Exclusion of other causes: especially infections (tuberculosis, fungal) and other granulomatous diseases (berylliosis, hypersensitivity pneumonitis, Crohn disease, etc.)

Situations Where Biopsy Can Be Avoided (Clinical Diagnosis)

Löfgren syndrome: erythema nodosum + bilateral hilar adenopathy + ankle periarthritis
Heerfordt syndrome: uveoparotid fever (uveitis + parotitis + fever + BHL)
Bilateral hilar adenopathy on chest radiograph without symptoms (after excluding lymphoma/TB)

Biopsy Sites (in order of preference - least invasive)

Transbronchial biopsy (TBB) - diagnostic in 40-90% of pulmonary sarcoidosis; preferred first-line approach
Endobronchial biopsy - even without visible lesions, yield ~40-60%
EBUS-guided transbronchial needle aspiration (EBUS-TBNA) - high yield for mediastinal nodes (>80%)
Skin, conjunctival biopsy (if lesions present - easy access)
Surgical lung biopsy (VATS) - reserved for diagnostic uncertainty
Liver, lymph node biopsy when clinically indicated

Laboratory Investigations

Test	Finding	Comment
Serum ACE (sACE)	Elevated in 30-80%	Produced by epithelioid macrophages; low specificity (also elevated in TB, histoplasmosis, diabetes, cirrhosis, silicosis); useful for monitoring, NOT diagnosis
Serum calcium	Elevated in ~10-15%	Due to ectopic 1,25-(OH)2 vitamin D by macrophages
Urinary calcium (24-hr)	Elevated (hypercalciuria)	More common than hypercalcemia
1,25-(OH)2 vitamin D	Elevated	Pathognomonic mechanism
LFTs (ALP)	Elevated in hepatic involvement
CBC	Lymphopenia, anemia, thrombocytopenia
LDH	Elevated in active disease	Non-specific
IFN-γ release assay (IGRA)	Done to exclude TB	Recommended at initial evaluation
BAL CD4:CD8 ratio	>3.5:1 (elevated)	Supportive (normal ~1.7:1); lymphocytosis in BAL
Gallium-67 scan	Panda sign + lambda sign	Replaced by FDG-PET in modern practice
FDG-PET	Identifies active inflammatory sites	Used to guide biopsy, assess disease activity, detect cardiac/extrapulmonary disease

No diagnostic biomarker currently exists for sarcoidosis - it remains a diagnosis of exclusion.

Fishman's, pp. 935-936; Murray & Nadel's, pp. 2130-2138

11. PROGNOSIS AND DISEASE COURSE

~50-60% of patients have spontaneous remission within 1-3 years, especially Stage I disease
~20-30% have chronic persistent disease requiring long-term therapy
~5-10% have progressive disease with irreversible organ damage
Prognostic indicators of poor outcome:
- Black race, older age at diagnosis
- Stage III/IV radiographic disease
- Lupus pernio (indicates chronic systemic disease)
- Cardiac sarcoidosis
- Neurosarcoidosis
- Pulmonary hypertension
- Requirement for treatment at diagnosis
Patients needing treatment at diagnosis have a 2-fold increased risk of death (Swedish registry data)

12. TREATMENT

When to Treat

Many patients are asymptomatic and do not require immediate treatment; spontaneous remission is common in the first 6 months. Treatment decision is based on:

Significant symptoms
Decline in pulmonary function (FVC or DLCO)
Threatened vital organ function (cardiac, neurologic, ocular, renal)
Hypercalcemia

First-Line: Corticosteroids

Prednisone remains the mainstay of treatment for sarcoidosis:

Initial dose: 20-40 mg/day (some guidelines use 0.5 mg/kg/day)
Response usually within 1 month
Taper slowly over months once improvement achieved
50% relapse rate when withdrawn after >2 years of therapy
Patients not responding to prednisone 40 mg/day are considered steroid-refractory

Second-Line: Steroid-Sparing (Cytotoxic) Agents

Used when:

1 year of corticosteroid therapy required
Significant steroid side effects
Steroid-refractory disease

Drug	Dose/Route	Main Uses	Key Toxicity
Methotrexate	10-15 mg/week (oral)	Most widely used; effective for pulmonary, ocular, cutaneous, neurologic, sinonasal disease	Hepatotoxicity, pulmonary toxicity, bone marrow suppression
Azathioprine	50-200 mg/day	Steroid-sparing, pulmonary and systemic disease	Hepatotoxicity, bone marrow suppression
Leflunomide	10-20 mg/day	Often combined with methotrexate	Peripheral neuropathy, hepatotoxicity
Mycophenolate mofetil	1-3 g/day	Pulmonary, cutaneous disease	GI side effects

Third-Line: Antimalarial Agents

Hydroxychloroquine (preferred) or chloroquine
Effective for: cutaneous disease, sinonasal disease, hypercalcemia, fatigue
Dose: hydroxychloroquine <5 mg/kg real body weight to minimize ocular toxicity
Routine ophthalmologic monitoring required

Biologic Agents

Anti-TNF agents: Infliximab and adalimumab are used for refractory sarcoidosis
Infliximab: Level 1 evidence from RCTs for pulmonary sarcoidosis (improves FVC)
Reserved for patients failing conventional immunosuppressive therapy

Other Interventions

Lung transplantation: For end-stage stage IV sarcoidosis; sarcoidosis can recur in transplanted lung
Cardiac pacemaker/ICD: For cardiac sarcoidosis with AV block or ventricular arrhythmias
Pulmonary rehabilitation: For patients with chronic pulmonary disability
Murray & Nadel's, pp. 2134-2138; Fishman's, pp. 940-944

13. SPECIAL SUBTYPES

Fibrocystic (Stage IV) Sarcoidosis

Extensive mid and upper lung scarring with bullous and cystic changes
Hilar retraction upward
Complicated by Aspergillus colonization (aspergilloma in bullae) and hemoptysis
Pulmonary hypertension is common in this stage

Sarcoidosis-Associated Pulmonary Hypertension (SAPH)

More common than previously recognized
Mechanisms: pulmonary vascular granulomas, extrinsic compression of pulmonary arteries by mediastinal nodes, hypoxic vasoconstriction, cardiac sarcoidosis, porto-pulmonary hypertension
Carries a particularly poor prognosis
Responds poorly to pulmonary arterial hypertension (PAH)-specific therapy

Necrotizing Sarcoid Granulomatosis

Rare variant with extensive necrosis within granulomas + vasculitis
Usually presents as lung nodules; generally a benign course

Parasarcoidosis Syndromes

Inflammatory manifestations not due to direct granulomatous involvement
Include: fatigue/sarcoidosis-associated fatigue (most common complaint, often refractory), small-fiber neuropathy, cognitive impairment
Refractory to standard anti-inflammatory treatment

14. DIFFERENTIAL DIAGNOSIS

Condition	Key Differentiating Feature
Tuberculosis	Caseating (necrotizing) granulomas; AFB positive; positive TST/IGRA
Hypersensitivity pneumonitis	Upper lobe granulomas + centrolobular nodules on HRCT; antigen exposure history; CD4:CD8 <1 in BAL
Berylliosis	Clinically/histologically identical to sarcoidosis; beryllium lymphocyte proliferation test (BeLPT) distinguishes
Lymphoma	No granulomas on biopsy; Reed-Sternberg cells; PET/CT pattern different
Histoplasmosis/Coccidioidomycosis	Fungal staining positive; serology
Wegener's/GPA	Necrotizing granulomatous vasculitis; c-ANCA/PR3-ANCA positive
Löfgren syndrome mimics	Always confirm with clinical criteria; erythema nodosum can occur in other conditions

15. SUMMARY MEMORY AIDS (High-Yield Points for Exams)

Noncaseating granuloma = pathologic hallmark - NO necrosis
Perilymphatic distribution on HRCT = most specific radiologic pattern
BAL CD4:CD8 >3.5:1 = characteristic immunological finding
sACE elevated in 30-80% but NOT specific; used for monitoring
Hypercalcemia = ectopic 1,25-(OH)2 Vit D from activated macrophages
Stage I = best prognosis (80% spontaneous remission); Stage IV = irreversible fibrosis
Löfgren syndrome = erythema nodosum + BHL + ankle arthritis = diagnose without biopsy
Heerfordt syndrome = uveoparotid fever = diagnose without biopsy
EBUS-TBNA = preferred bronchoscopic approach for mediastinal node sampling (>80% yield)
Prednisone 20-40 mg/day = first-line treatment; taper slowly; 50% relapse on withdrawal
Methotrexate = most used steroid-sparing agent
Infliximab = anti-TNF biologic for refractory disease (level 1 evidence)
Lupus pernio = chronic severe sarcoidosis marker; violaceous facial plaques
Cardiac sarcoidosis = can cause sudden death from arrhythmia; requires screening ECG in all patients
Disease results from genetic susceptibility (HLA genes) + environmental/microbial triggers → aberrant Th1-driven immune response → noncaseating granulomatous inflammation

Sources:

Fishman's Pulmonary Diseases and Disorders, 2-Volume Set (Chapter 53: Systemic Sarcoidosis), pp. 922-944
Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume (Chapter 93), pp. 2128-2145

This is a shared conversation. Sign in to Orris to start your own chat.